• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The EPMA journal. >Biomarkers for prediction and targeted prevention of Alzheimer’s and Parkinson’s diseases: evaluation of drug clinical efficacy
【24h】

Biomarkers for prediction and targeted prevention of Alzheimer’s and Parkinson’s diseases: evaluation of drug clinical efficacy

机译：用于预测和靶向预防阿尔茨海默氏病和帕金森氏病的生物标志物：药物临床疗效评估

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Neurodegenerative diseases like Parkinson’s disease (PD) and Alzheimer’s disease (AD) are considered disorders of multifactorial origin, inevitably progressive and having a long preclinical period. Therefore, the availability of biological markers or biomarkers (BMs) for early disease diagnosis will impact the management of AD and PD in several dimensions; it will 1) help to capture high-risk individuals before symptoms develop, a stage where prevention efforts might be expected to have their greatest impact; 2) provide a measure of disease progression that can be evaluated objectively, while clinical measures are much less accurate; 3) help to discriminate between true AD or PD and other causes of a similar clinical syndrome; 4) delineate pathophysiological processes responsible for the disease; 5) determine the clinical efficacy of novel, disease-modifying (neuroprotective) strategies. In the long run the availability of reliable BMs will significantly advance the research and therapeutics of AD and PD.
机译：帕金森氏病（PD）和阿尔茨海默氏病（AD）等神经退行性疾病被认为是多因素起源的疾病，不可避免地会进行性疾病并且临床前期较长。因此，用于疾病早期诊断的生物标志物或生物标志物（BMs）的可用性将在多个方面影响AD和PD的管理。它将有助于1）在症状发作之前帮助捕获高危人群，在这一阶段，预防工作有望发挥最大作用; 2）提供可以客观评估的疾病进展指标，而临床指标的准确性要差得多; 3）帮助区分真正的AD或PD与其他类似临床综合征的病因; 4）描绘导致疾病的病理生理过程; 5）确定新颖的疾病缓解（神经保护）策略的临床疗效。从长远来看，可靠的BM的可用性将极大地促进AD和PD的研究和治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号